StreetInsider.com News Articles

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Fri, 15 May 2026 07:00:00 -0400

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
BASECAMP remains on track to complete enrollment in Q3 2026
The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027

TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Fri, 15 May 2026 07:00:00 -0400

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
BASECAMP remains on track to complete enrollment in Q3 2026
The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Fri, 15 May 2026 07:00:00 -0400

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
BASECAMP remains on track to complete enrollment in Q3 2026
The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Fri, 15 May 2026 07:00:00 -0400

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
BASECAMP remains on track to complete enrollment in Q3 2026
The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Fri, 15 May 2026 07:00:00 -0400

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
BASECAMP remains on track to complete enrollment in Q3 2026
The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

Fri, 15 May 2026 07:00:00 -0400

Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
BASECAMP remains on track to complete enrollment in Q3 2026
The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
Current cash available of $69.9M (Cdn $97.5M) provides runway through 2027

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

Thu, 09 Apr 2026 07:00:00 -0400

TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the Bloom Burton & Co. Healthcare Investor Conference taking place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada.

Satellos Co-founder and CEO Frank Gleeson will provide a presentation on April 21 and along with Liz Williams, Chief Financial Officer, will participate in one-on-one meetings during the conference.

2026 Bloom Burton & Co. Healthcare

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy